Management of Symptomatic Bradycardia

Initial Assessment and Management

• The American Heart Association recommends evaluating if bradycardia is causing symptoms or hemodynamic compromise, such as altered mental status, ischemic chest discomfort, acute heart failure, hypotension, or other signs of shock, and maintaining patent airway and assisting breathing as necessary, providing supplemental oxygen if the patient is hypoxemic or shows signs of increased work of breathing, establishing cardiac monitoring to identify rhythm, monitor blood pressure, and measure oxygen saturation, establishing IV access for medication administration, obtaining a 12-lead ECG if available, and identifying and treating underlying causes of bradycardia 1

Treatment Algorithm

First-Line Treatment

• The American College of Cardiology recommends administering atropine 0.5-1 mg IV for symptomatic bradycardia, repeating every 3-5 minutes as needed up to a maximum total dose of 3 mg, with doses of atropine <0.5 mg potentially resulting in further slowing of heart rate and should be avoided 2, 3, 4, 5

If Bradycardia Persists Despite Atropine

• The American Heart Association suggests initiating IV infusion of β-adrenergic agonists, including dopamine, epinephrine, and isoproterenol, with caution in patients with coronary artery disease, and considering transcutaneous pacing in unstable patients who do not respond to atropine, and preparing for transvenous pacing if the patient does not respond to drugs or TCP 2, 6

Special Considerations

Type of AV Block

• Atropine is likely to be effective in sinus bradycardia, conduction block at the level of the AV node, or sinus arrest, but may be ineffective in type II second-degree or third-degree AV block with new wide-QRS complex where the block is likely in non-nodal tissue 5

Specific Clinical Scenarios

• The American College of Cardiology recommends avoiding atropine in heart transplant patients without evidence of autonomic reinnervation, as it may cause paradoxical high-degree AV block, and using atropine cautiously in inferior myocardial infarction as increased heart rate may worsen ischemia or increase infarction size 2, 5

Potential Complications and Pitfalls

• Atropine administration should not delay implementation of external pacing for patients with poor perfusion, and excessive doses of atropine (>3 mg) may cause central anticholinergic syndrome, including confusion, agitation, and hallucinations 5

Monitoring and Follow-up

• The American Heart Association recommends continuing cardiac monitoring during and after treatment, evaluating response to therapy by monitoring heart rate, blood pressure, and resolution of symptoms 1

Dopamine Administration for Symptomatic Bradycardia

Initial Dose and Titration

• The recommended initial dose of dopamine for symptomatic bradycardia is 5-10 mcg/kg/min, which should be titrated according to the patient's response, as recommended by the American Heart Association 7, 8

Pharmacological Effects

• At lower doses (1-2 mcg/kg/min), dopamine has predominantly vasodilatory effects, while at doses of 5-20 mcg/kg/min, enhanced chronotropy and inotropy predominate, according to the American College of Cardiology 9
• Higher doses of dopamine may cause profound vasoconstriction and proarrhythmias, as noted by the American College of Cardiology 9

Alternative Treatments

• If dopamine is ineffective, consider epinephrine (0.1-0.5 mcg/kg/min), as suggested by the American Heart Association 7, 8

Dosis Inicial de Epinefrina para Bradicardia Sintomática Refractaria a Atropina

Algoritmo de Tratamiento

• La American Heart Association recomienda iniciar la infusión de epinefrina a 2-10 µg/min para bradicardia sintomática que no responde a atropina, titulando según la respuesta hemodinámica del paciente 10, 11
• Administrar atropina 0.5-1 mg IV como primera línea, repitiendo cada 3-5 minutos hasta una dosis máxima total de 3 mg, según las guías de la American Heart Association 10, 11
• Las dosis menores de 0.5 mg de atropina pueden paradójicamente disminuir más la frecuencia cardíaca y deben evitarse, según el Journal of the American College of Cardiology 12

Consideraciones Prácticas

• La dosis inicial recomendada de epinefrina es 2-10 µg/min en infusión IV continua, según las guías internacionales de consenso en reanimación cardiopulmonar 10, 11
• La American Heart Association también sugiere dopamina (2-10 µg/kg/min) como alternativa a la epinefrina 10, 11

Contexto Clínico Importante

• La epinefrina es particularmente útil en bradicardia hemodinámicamente inestable que no responde a dosis completas de atropina, según la American Heart Association 10, 11
• En pacientes con trasplante cardíaco, la atropina puede causar paradójicamente bloqueo AV de alto grado, y se prefiere la epinefrina, según la American Heart Association 10, 11

Advertencias Críticas

• El marcapasos transcutáneo debe considerarse simultáneamente cuando la atropina falla, según la American Heart Association 10, 11

Dopamine for Bradycardia

Treatment Algorithm for Symptomatic Bradycardia

• The American Heart Association recommends administering atropine 0.5-1 mg IV as initial therapy for symptomatic bradycardia, with repeat doses every 3-5 minutes up to a maximum total dose of 3 mg 13, 14, 15
• Dopamine is a second-line agent for symptomatic bradycardia that has failed to respond to atropine, with a recommended infusion rate of 2-10 mcg/kg/min titrated to hemodynamic response 13, 14, 15
• The American College of Cardiology suggests that dopamine provides both chronotropic and inotropic effects through beta-1 adrenergic stimulation at doses of 2-10 mcg/kg/min 15

Evidence Quality and Comparative Effectiveness

• A randomized feasibility trial of 82 patients with atropine-refractory bradycardia found identical survival rates (approximately 70%) whether treated with dopamine or transcutaneous pacing 14

Clinical Scenarios Where Atropine (and Therefore Dopamine) May Be Needed

• Atropine is likely effective for sinus bradycardia, AV nodal block, and sinus arrest 13, 15
• Atropine is unlikely effective for type II second-degree AV block, third-degree AV block with wide QRS complex, and post-cardiac transplant patients 13, 14, 15

Critical Warnings

• Increasing heart rate with rate-accelerating drugs in acute coronary ischemia or MI may worsen ischemia or increase infarct size 13, 15
• Higher dopamine doses (>10 mcg/kg/min) cause vasoconstriction and arrhythmias 15

Practical Implementation

• The American Heart Association recommends giving atropine first, 0.5-1 mg IV, repeat every 3-5 minutes to maximum 3 mg, and if no response, start dopamine 5-10 mcg/kg/min IV infusion 13, 14, 15
• Dopamine should be titrated every 2-5 minutes, increasing by 2-5 mcg/kg/min based on heart rate and blood pressure 15

Dopamine vs Epinephrine in Ischemic Cardiomyopathy with Bradycardia

Treatment Algorithm

• The American College of Cardiology recommends administering atropine 0.5-1 mg IV as first-line therapy, repeating every 3-5 minutes up to a maximum total dose of 3 mg, for patients with symptomatic bradycardia or hemodynamic compromise 16, 17, 18
• Atropine is reasonable to increase sinus rate in patients with symptomatic bradycardia or hemodynamic compromise, according to the American College of Cardiology and Circulation guidelines 16, 17
• Both dopamine and epinephrine receive only Class IIb (may be considered) recommendations in patients with sinus node dysfunction and symptoms or hemodynamic compromise, as stated by the American College of Cardiology and Circulation 16, 17, 18

Choosing Between Dopamine and Epinephrine

• If inotropic support is required, dopamine is the more appropriate choice, with a starting dose of 5 mcg/kg/min IV, increasing by 5 mcg/kg/min every 2 minutes, according to the American College of Cardiology and Circulation guidelines 16, 17, 19
• Dopamine provides dose-dependent effects with mixed alpha-adrenergic, beta-adrenergic, and dopaminergic actions, as described by the American College of Cardiology and Circulation 17, 20
• Epinephrine has strong alpha-adrenergic effects causing more profound vasoconstriction, and its dose is 2-10 mcg/min IV or 0.1-0.5 mcg/kg/min IV titrated to desired effect, according to the American College of Cardiology and Circulation guidelines 16, 17, 19

Practical Clinical Decision-Making

• The American College of Cardiology and Circulation recommend choosing dopamine over epinephrine because dopamine has more titratable, dose-dependent effects allowing better control, and lower doses provide chronotropy with less vasoconstriction than epinephrine 17, 20
• Isoproterenol may be preferable to both dopamine and epinephrine in this scenario, as it provides chronotropic and inotropic effects without vasopressor effects, with a dose of 20-60 mcg IV bolus or infusion of 1-20 mcg/min based on heart rate response, according to the American College of Cardiology and Circulation guidelines 16, 17, 19

Common Pitfalls to Avoid

• The American College of Cardiology and Circulation guidelines advise not to exceed dopamine doses of 20 mcg/kg/min, as higher doses cause excessive vasoconstriction and arrhythmias 16, 17, 20

Transcutaneous Pacing for Symptomatic Bradycardia

Clinical Presentation and Diagnosis

• The American Heart Association guidelines recommend transcutaneous pacing (TCP) for unstable patients with symptomatic bradycardia who do not respond to atropine (Class IIa, Level of Evidence B) 21, 22
• Patients with severe hypotension (systolic BP < 80 mm Hg) and signs of shock are considered hemodynamically unstable 23, 24
• The presence of palpable pulses indicates some degree of perfusion, but the patient is still critically compromised 24

Treatment Guidelines

• The American College of Cardiology/American Heart Association (ACC/AHA) guidelines classify symptomatic bradycardia with hypotension unresponsive to atropine as a Class II indication for transcutaneous pacing 23, 24
• TCP can be applied rapidly without the delays and complications associated with transvenous pacing, making it a critical intervention for deteriorating patients 23, 24
• TCP serves as an urgent expedient while preparing for definitive therapy if needed 23, 24

Clinical Algorithm

• The first-line treatment for symptomatic bradycardia is atropine 0.5-1 mg IV, repeated every 3-5 minutes up to a maximum of 3 mg 21, 22
• If atropine fails, transcutaneous pacing is the next recommended step 21, 22
• Alternative or adjunctive treatments include β-adrenergic agonists (dopamine 5-10 mcg/kg/min or epinephrine 2-10 mcg/min) 21, 22

Important Considerations

• TCP is a temporizing measure only and may require sedation/analgesia due to pain in conscious patients 21, 22
• Atropine may be ineffective in certain types of AV block, and its failure to respond suggests either infranodal block or severe nodal dysfunction 21, 22
• Delaying TCP while giving additional atropine doses can be harmful in unstable patients 21, 22

Adrenaline Use in Bradycardia

Treatment Algorithm

• The American Heart Association recommends administering atropine 0.5-1 mg IV as initial treatment for symptomatic bradycardia, with repeat doses every 3-5 minutes up to a maximum total dose of 3 mg 25, 26
• Epinephrine is specifically recommended when atropine and transcutaneous pacing fail or pacing is unavailable, with a starting dose of 2-10 mcg/min IV infusion 25

Clinical Context

• The American College of Cardiology recommends epinephrine over dopamine in cases of severe hypotension with bradycardia, and when both strong chronotropic and inotropic support are urgently needed 25
• The European Society of Cardiology recommends avoiding epinephrine as a first-line inotrope or vasopressor in cardiogenic shock, restricting its use to cardiac arrest scenarios 27

Critical Warnings and Pitfalls

• The American Heart Association recommends using epinephrine with extreme caution in acute coronary ischemia or myocardial infarction, as it may worsen ischemia or increase infarct size 25, 28

Special Population

• The American College of Cardiology recommends avoiding atropine in heart transplant patients without autonomic reinnervation, as it may cause paradoxical high-degree AV block or sinus arrest, and instead using epinephrine as the preferred agent 26

Pacing in Emergency Medicine

Indications and Considerations for Pacing

• The American Heart Association recommends initiating transcutaneous pacing (TCP) immediately for unstable patients with symptomatic bradycardia who remain hemodynamically unstable despite atropine administration (Class IIa recommendation) 29, 30
• For hemodynamically unstable tachycardia, the American Heart Association indicates immediate synchronized cardioversion, not pacing, as the appropriate intervention in the ED 29, 30
• Overdrive pacing may be effective for torsades de pointes (polymorphic VT with long QT) when associated with bradycardia or pause-dependent episodes, and is adjunctive to IV magnesium and correction of underlying causes 29
• The American College of Cardiology suggests considering pacing when polymorphic VT is precipitated by pauses in rhythm, and when accompanied by bradycardia in polymorphic VT with acquired long QT syndrome 29, 30
• Isoproterenol or ventricular pacing can terminate torsades associated with bradycardia and drug-induced QT prolongation, but isoproterenol should be avoided in familial long QT syndrome—use pacing and β-blockers instead 29, 30

Atropine in Neurogenic Shock

Introduction to Atropine Therapy

• The American College of Cardiology recommends atropine as first-line therapy for symptomatic bradycardia in neurogenic shock, but it has significant limitations and often fails in this specific population, requiring early consideration of alternative agents like aminophylline or vasopressors 31, 32
• Atropine should be administered at 0.5-1 mg IV for symptomatic bradycardia in neurogenic shock, repeated every 3-5 minutes up to a maximum total dose of 3 mg, representing a Class IIa recommendation from the ACC/AHA for bradycardia with hemodynamic compromise 31, 32

First-Line Treatment Algorithm

• The American College of Cardiology and the American Heart Association recommend atropine as a reasonable treatment option for bradycardia in neurogenic shock, with a dosing regimen of 0.5-1 mg IV, repeated as necessary, up to a total dose of 3 mg 31, 32

Alternative Therapies

• The American College of Cardiology and the American Heart Association guidelines list aminophylline 6 mg/kg in 100-200 mL IV over 20-30 minutes as a treatment for bradycardia in spinal cord injury, reflecting the unique pathophysiology of neurogenic shock 31, 32
• Theophylline dosing often achieves therapeutic effect at serum levels below the usual 10-20 mcg/mL range in this population 31, 32

Vasopressor and Inotrope Therapy

• If bradycardia persists despite atropine, initiate dopamine 5-20 mcg/kg/min or epinephrine 2-10 mcg/min IV infusion, as recommended by the American College of Cardiology and the American Heart Association 31, 32
• Dopamine provides both chronotropic and inotropic effects at 5-20 mcg/kg/min, starting at 5 mcg/kg/min and increasing by 5 mcg/kg/min every 2 minutes, according to the American College of Cardiology and the American Heart Association guidelines 31, 32

Special Considerations

• In heart transplant patients without autonomic reinnervation, atropine should not be used as it may cause paradoxical high-degree AV block, and epinephrine should be used instead, as recommended by the American College of Cardiology and the American Heart Association 31, 32
• In acute coronary ischemia or MI, increasing heart rate with atropine may worsen ischemia or increase infarct size, and the total atropine dose should be limited to 0.03-0.04 mg/kg in patients with coronary artery disease, according to the American College of Cardiology and the American Heart Association guidelines 31, 32

Management of Symptomatic Bradycardia

Initial Assessment and Diagnosis

• The American Heart Association recommends that symptomatic bradycardia be identified by documenting heart rate typically <50 beats/min with concurrent signs of poor perfusion, including altered mental status, ischemic chest discomfort, acute heart failure, hypotension, or shock, with correlation between symptoms and bradycardia being the critical determinant 33, 34

Definitive Management: Permanent Pacing

• The American College of Cardiology recommends permanent pacemaker implantation for symptomatic bradycardia persisting after excluding reversible causes, high-grade AV block with symptoms, sinus node dysfunction with documented symptomatic bradycardia, and bifascicular block with intermittent complete heart block and symptomatic bradycardia 33, 34
• The correlation between symptoms and documented bradycardia is essential before proceeding to permanent pacing, as asymptomatic bradycardia, even with heart rate <40 bpm, requires no treatment, which is common in athletes and during sleep 33, 34

ACLS Dosing for Symptomatic Bradycardia

Second-Line Treatment: Vasopressors/Inotropes

• The American Heart Association recommends initiating dopamine 5-10 mcg/kg/min IV infusion or epinephrine 2-10 mcg/min IV infusion if atropine fails to resolve symptomatic bradycardia, titrating to hemodynamic response 35
• For patients with symptomatic bradycardia, dopamine has a therapeutic range of 2-10 mcg/kg/min for chronotropic effect, as recommended by the American College of Cardiology 35
• The American Heart Association suggests that epinephrine may be preferred over dopamine in severe hypotension requiring both strong chronotropic and inotropic support, with a recommended dose of 2-10 mcg/min 35

Special Clinical Scenarios

• For bradycardia refractory to atropine in spinal cord injury patients, the American College of Cardiology recommends considering aminophylline or theophylline, with a suggested dose of theophylline 100-200 mg slow IV injection (maximum 250 mg) 35
• The American Heart Association recommends using theophylline to restore sinus rate and reduce pacemaker need in post-transplant bradycardia, with a suggested dose of 100-200 mg slow IV injection (maximum 250 mg) 35

Management of Symptomatic Bradycardia

Initial Assessment and Treatment

• For a patient with a heart rate of 45 bpm, the American Heart Association recommends first assessing if the patient is symptomatic or hemodynamically unstable, and if symptomatic, administering atropine 0.5-1 mg IV as first-line therapy, repeating every 3-5 minutes up to a maximum total dose of 3 mg 36
• The American College of Cardiology suggests that symptomatic bradycardia includes altered mental status, ischemic chest discomfort, acute heart failure, hypotension, syncope, dizziness, or dyspnea, and requires immediate treatment with atropine 36
• Ensure adequate oxygenation and establish IV access before pharmacologic intervention, as recommended by the American Heart Association 36

Pharmacologic Treatment

• Atropine is the first-line medication for symptomatic bradycardia, with a dose of 0.5-1 mg IV push, and can be repeated every 3-5 minutes as needed, with a maximum total dose of 3 mg, as recommended by the American Heart Association 36
• The American College of Cardiology recommends that doses less than 0.5 mg may paradoxically worsen bradycardia and should be avoided 36
• If atropine fails to resolve symptomatic bradycardia, the American Heart Association suggests initiating chronotropic infusions, such as dopamine or epinephrine, with dopamine being the preferred agent for most situations 36
• The American College of Cardiology recommends that dopamine be started at an initial dose of 5-10 mcg/kg/min IV infusion, and titrated to effect, with a maximum dose of 20 mcg/kg/min due to excessive vasoconstriction and arrhythmia risk 36

Special Considerations

• The American Heart Association recommends that if a patient requires more than atropine, such as continuous infusions of dopamine or epinephrine, immediate transfer to ICU or step-down unit is necessary, as these infusions require continuous cardiac monitoring 36
• The American College of Cardiology suggests that transcutaneous pacing pads can be placed prophylactically in high-risk patients, but actual pacing typically requires transfer to higher level of care, as recommended by the Journal of the American College of Cardiology 37
• Bradycardia with hypotension and signs of shock is associated with increased mortality, and aggressive treatment and transfer to higher level of care is essential, as recommended by the American Heart Association [38] [39]

Critical Warnings and Pitfalls

• The American College of Cardiology recommends avoiding the use of atropine in acute coronary ischemia or MI without caution, as increased heart rate may worsen ischemia or increase infarct size, and limiting total dose to 0.03-0.04 mg/kg in patients with coronary artery disease 38
• The American Heart Association suggests not delaying transcutaneous pacing in unstable patients while giving multiple atropine doses, and considering pacing simultaneously when atropine fails 36

Indications and Contraindications for Atropine Use in Acute Coronary Syndrome

Indications (Class I)

• Sinus bradycardia with hemodynamic compromise (e.g., low cardiac output, peripheral hypoperfusion, hypotension, or frequent premature ventricular contractions) occurring during an acute myocardial infarction is a strong indication for intravenous atropine (0.5–1 mg) to restore adequate heart rate and perfusion. – American College of Cardiology 40

• Inferior myocardial infarction with symptomatic type I second‑degree AV block (nodal‑level block) responds favorably to atropine, which improves AV nodal conduction and alleviates symptoms. – American College of Cardiology 40

• Bradycardia‑induced hypotension after nitroglycerin administration in the setting of acute coronary syndrome is appropriately treated with atropine to raise heart rate and blood pressure. – American College of Cardiology 40

Contraindications (Class III)

• Type II second‑degree AV block and third‑degree AV block with a wide QRS complex (infranodal or His‑Purkinje block) should not be treated with atropine, as vagolytic therapy does not improve conduction and may worsen the block. – American College of Cardiology 40

• Patients with infranodal AV block (type II second‑degree or third‑degree with wide QRS) must be excluded before administering atropine; alternative pacing or pharmacologic strategies are required. – American College of Cardiology 40 (duplicate citation merged for clarity)

Atropine Use in Acute Coronary Syndrome Patients with Symptomatic Bradycardia

Indications (When Treatment Is Required)

• Atropine is indicated only for symptomatic bradycardia in ACS (e.g., hypotension, altered mental status, worsening chest pain/ischemia, acute heart failure, or frequent ventricular ectopy/escape rhythms) – asymptomatic HR ≈ 52 bpm is a Class III (contraindicated) indication. 41
• Hypotension defined as systolic BP < 80‑90 mm Hg qualifies for treatment. [41][42]
• Altered mental status caused by bradycardia warrants atropine. 42
• Ongoing chest pain or worsening myocardial ischemia due to bradycardia is an indication. 41
• Acute heart failure attributable to low heart rate justifies atropine use. 42
• Frequent ventricular ectopy or escape rhythms associated with bradycardia are treatment triggers. 41

Contraindications (When Atropine Should Not Be Used)

• Type II second‑degree AV block – infranodal conduction will not improve and may deteriorate with atropine. (Class III) [41][42]
• Third‑degree AV block with wide QRS complex – indicates infranodal block; atropine is ineffective and potentially harmful. (Class III) [41][42]
• Anterior myocardial infarction with new bundle‑branch block – suggests infranodal pathology; atropine is contraindicated. (Class III) 41

Expected Efficacy (Conditions Likely to Respond)

• Sinus bradycardia in ACS generally responds to atropine. (Class I) [41][42]
• First‑degree AV block is amenable to atropine therapy. (Class I) 42
• Mobitz I (Wenckebach) second‑degree AV block (nodal‑level) is likely to improve with atropine. (Class I) [41][42]
• Inferior MI‑related bradycardia (typically vagally mediated) responds well to atropine. (Class I) 41

Dosing Strategy in the ACS Context

• Initial dose: 0.5 – 1 mg IV push; doses < 0.5 mg may paradoxically worsen bradycardia. (Class I) [41][42]
• Repeat dosing: Every 3‑5 minutes as needed, titrating to effect. (Class I) 42
• Target heart rate: Approximately 60 bpm; avoid aggressive rate increases that could raise myocardial oxygen demand. (Class I) 41
• Maximum cumulative dose in ACS: 2‑3 mg (lower than the standard 3 mg ceiling for other settings). (Class I) [41][42]

Monitoring & Adverse Effects

• Excessive tachycardia can increase myocardial oxygen consumption and potentially enlarge infarct size; therefore heart rate should be closely monitored and kept near the target. (Class I) [41][42]

Alternative Therapies When Atropine Fails or Is Contraindicated

• Transcutaneous pacing – Class IIa recommendation for unstable patients who do not respond to atropine. 42
• Dopamine infusion (5‑10 µg/kg/min) – provides both chronotropic and inotropic support when atropine is ineffective. (Class IIa) 42
• Epinephrine infusion (2‑10 µg/min) – indicated for severe hypotension requiring combined chronotropic and inotropic effects. (Class IIa) 42

Clinical Pearls / Pitfalls to Avoid

• Do not administer atropine for asymptomatic bradycardia; preserving parasympathetic tone may protect against ventricular fibrillation and infarct extension. (Class III) 41
• Do not delay transcutaneous pacing in hemodynamically unstable patients while repeatedly dosing atropine. (Class IIa) 42
• Avoid atropine in the presence of wide‑complex escape rhythms or Type II/third‑degree AV block, as these indicate infranodal disease where the drug is ineffective and may be harmful. (Class III) [41][42]

Management of Medication‑Induced Bradycardia in Parkinson’s Disease

Identification of the Offending Agent

• Quetiapine (Seroquel) should be tapered and discontinued as the most reversible cause of bradycardia in this setting; the American Geriatrics Society highlights atypical antipsychotics as primary culprits for drug‑induced bradycardia. 43
• Quetiapine can directly depress cardiac conduction, making it the likely primary offender when bradycardia develops in patients receiving both Sinemet and quetiapine. 43
• The additive bradycardic effect of combined rate‑slowing agents (e.g., donepezil + beta‑blockers) illustrates that any medication with heart‑rate‑lowering properties can compound bradycardia; this principle extends to quetiapine when used with other agents. 43

Review of Concomitant Bradycardic Medications

• Beta‑blockers (e.g., metoprolol, atenolol, propranolol) should be dose‑reduced or stopped if not essential for heart‑failure or post‑MI therapy; the American Geriatrics Society and the American Heart Association (Circulation) recommend this to mitigate drug‑induced bradycardia. [43][44]
• Non‑dihydropyridine calcium‑channel blockers (diltiazem, verapamil) should be reduced or substituted with alternative antihypertensives to avoid additive bradycardic effects. 44
• Digoxin therapy requires serum level assessment and possible dose reduction when elevated, as it can exacerbate conduction slowing. 44
• Amiodarone frequently induces bradycardia and may need dose adjustment or discontinuation in the context of symptomatic bradycardia. 45

Definition and Immediate Assessment of Symptomatic Bradycardia

• Symptomatic bradycardia is defined as a heart rate < 50 bpm accompanied by signs of poor perfusion (altered mental status, ischemic chest discomfort, acute heart‑failure, systolic BP < 80‑90 mmHg, syncope, dizziness, or dyspnea). This definition follows the American College of Cardiology guidance. 46

Acute Pharmacologic Management

• Administer atropine 0.5–1 mg IV immediately for hemodynamically unstable patients, repeating every 3–5 minutes up to a total of 3 mg; doses < 0.5 mg may paradoxically worsen bradycardia. This recommendation aligns with ACC protocols. 46

Monitoring and Follow‑Up

• Obtain a baseline 12‑lead ECG to identify the type of bradycardia and assess QTc before initiating therapy. (Guideline reference implied by monitoring recommendations.)
• Monitor heart rate and blood pressure weekly for the first month, then monthly once stable; this schedule is endorsed by the American Heart Association (Circulation). 45

Indications for Permanent Pacing

• Permanent pacemaker implantation is indicated when symptomatic bradycardia persists after all reversible causes have been addressed, particularly in the presence of high‑grade AV block, sinus node dysfunction with documented symptoms, or bifascicular block with intermittent complete heart block. This recommendation follows the European Society of Cardiology guideline. 47

Management of Unstable Bradycardia Refractory to Atropine

First‑line Therapy: Atropine

• The American Heart Association recommends an immediate IV bolus of 0.5–1 mg atropine for symptomatic bradycardia with hemodynamic compromise (e.g., altered mental status, ischemic chest pain, acute heart failure, hypotension or shock), repeating every 3–5 minutes as needed up to a total of 3 mg. 48

Second‑line Chronotropic Agents (When Atropine Fails)

• Dopamine: Initiate at 5–10 µg·kg⁻¹·min⁻¹ IV infusion and titrate up to a maximum of 20 µg·kg⁻¹·min⁻¹; this regimen is endorsed by the American Heart Association. 48
• Epinephrine (adrenaline): Start at 2–10 µg·min⁻¹ IV infusion; preferred in cases of severe hypotension that require combined chronotropic and inotropic support, per American Heart Association guidance. 48

Transcutaneous Pacing

• Transcutaneous pacing should be started concurrently when atropine is ineffective and must not be delayed while additional atropine doses are administered. The American Heart Association assigns a Class IIa recommendation for unstable patients who do not respond to atropine. 48

Noradrenaline as an Alternative Agent

• Noradrenaline can be considered a reasonable alternative when dopamine or epinephrine are unavailable for unstable bradycardia refractory to atropine, although it is not listed as a first‑line option in the 2015 American Heart Association ACLS guidelines. 48
• Suggested dosing (extrapolated from shock protocols) is an IV infusion of 0.1–0.5 µg·kg⁻¹·min⁻¹, titrated to hemodynamic response with close monitoring of heart rate and blood pressure every 2–5 minutes. 48
• Evidence supporting noradrenaline for bradycardia is limited compared with dopamine or epinephrine. 48

Situations in Which Atropine Is Ineffective

• Second‑degree AV block type II (Mobitz II) with a wide QRS complex indicates infranodal block; atropine does not improve conduction. 48
• Third‑degree AV block with a wide QRS complex is also unresponsive to atropine and may be harmful if used. 48

Risks of Chronotropic Stimulation in Acute Coronary Syndromes

• Raising heart rate with any chronotropic agent (atropine, dopamine, epinephrine, or noradrenaline) can exacerbate myocardial ischemia or enlarge infarct size in patients with acute coronary syndrome. 48

Practical Decision Algorithm in Resource‑Limited Settings

Management of Sedation‑Induced Bradycardia in Post‑Myocardial Infarction Patients

Assessment of Bradycardia

• Identify symptomatic bradycardia (heart rate < 50 bpm) by the presence of hypotension, altered mental status, worsening ischemic symptoms, or hemodynamic compromise; immediate reduction or cessation of remifentanil and administration of atropine 0.5–1 mg IV is recommended. – American College of Cardiology (Class I, Level A) 49
• Evaluate for ongoing or worsening chest pain/ischemia and for frequent ventricular ectopy or escape rhythms as indicators of symptomatic bradycardia. – American College of Cardiology (Class I) 49
• Asymptomatic bradycardia does not require treatment; intervening is a Class III (contraindicated) recommendation in the post‑MI setting. – American College of Cardiology (Class III) 50

Drug‑Specific Considerations

Remifentanil

• Remifentanil induces bradycardia through vagal stimulation and prolongation of sino‑atrial node recovery time, with effects appearing within minutes of infusion. – European Society of Cardiology (Level B) 51
• Reducing the remifentanil infusion rate by ≈ 50 % or temporarily stopping the infusion resolves bradycardia rapidly (ultra‑short half‑life 3–10 min). – European Society of Cardiology (Level B) 51
• After resolution, remifentanil should not be restarted at the previous rate; the dose should be reduced by at least 50 % or the agent switched to fentanyl, which has a milder bradycardic profile. – European Society of Cardiology (Level B) 51

Fentanyl (Alternative Opioid)

• Switching to fentanyl (bolus 25–100 µg, infusion 25–300 µg/h) provides adequate analgesia with less pronounced bradycardic effect compared with remifentanil. – European Society of Cardiology (Level B) 51

Midazolam

• Midazolam produces less hypotension than propofol and is often selected for hemodynamic stability in post‑MI patients, though it contributes to overall sedative‑induced cardiovascular depression. – European Society of Cardiology (Level B) 51

Pharmacologic Treatment Algorithm

First‑Line: Atropine

• Administer atropine 0.5–1 mg IV push immediately for symptomatic bradycardia; repeat every 3–5 min as needed, not exceeding a total dose of 2–3 mg (lower than the standard 3 mg maximum) in post‑MI patients. – American College of Cardiology (Class I) 49
• Doses < 0.5 mg may paradoxically worsen bradycardia via a parasympathomimetic effect and should be avoided. – American College of Cardiology (Class I) 49
• Target a heart rate of ≈ 60 bpm; avoid aggressive rate increases that could raise myocardial oxygen demand and exacerbate ischemia. – American College of Cardiology (Class I) 49
• Atropine is most effective for sinus bradycardia occurring within the first 6 hours after MI onset (related to ischemia, reperfusion reflexes, or drug effects). – American College of Cardiology (Class I) 49

Situations Where Atropine Is Ineffective or Contraindicated

• Type II second‑degree AV block (Mobitz II) with wide QRS complexes indicates infranodal block; atropine will not improve conduction (Class III). – American College of Cardiology (Class III) 49
• Third‑degree AV block with wide QRS complex is a contraindication to atropine (Class III). – American College of Cardiology (Class III) 49

Second‑Line: Chronotropic Infusions (When Atropine Fails)

• If bradycardia persists after atropine and cessation of remifentanil, initiate dopamine infusion 5–10 µg/kg/min IV, titrating every 2–5 min to hemodynamic response (max 20 µg/kg/min). – American College of Cardiology (Class IIa) 49
• Epinephrine 2–10 µg/min IV is preferred when severe hypotension requires combined chronotropic and inotropic support. – American College of Cardiology (Class IIa) 49

Third‑Line: Transcutaneous Pacing

• Apply transcutaneous pacing immediately for hemodynamically unstable patients who remain bradycardic despite atropine; do not delay pacing while administering multiple atropine doses. – American College of Cardiology (Class IIa) 49
• Transcutaneous pacing is a Class IIa recommendation for unstable bradycardia unresponsive to atropine, especially in post‑MI patients receiving thrombolytics, as it avoids vascular‑access complications. – American College of Cardiology (Class IIa) 49

Safety and Physiologic Considerations

• All chronotropic agents (atropine, dopamine, epinephrine) increase myocardial oxygen demand and may worsen ischemia or enlarge infarct size in acute MI; therefore, titrate to the minimally effective heart rate (~60 bpm). – American College of Cardiology (Class I) 49
• Parasympathetic (vagal) tone may protect against ventricular fibrillation and infarct extension in the early post‑MI period, supporting the recommendation to withhold treatment for asymptomatic bradycardia. – American College of Cardiology (Class I) 49
• Do not exceed a total atropine dose of 2–3 mg in post‑MI patients; higher doses increase the risk of tachycardia‑induced ischemia. – American College of Cardiology (Class I) 49

Transcutaneous Pacing and Advanced Management of Hemodynamically Unstable Symptomatic Bradycardia

Transcutaneous Pacing Recommendations

• Class IIa recommendation: For patients with hemodynamic instability who do not respond to atropine, immediate initiation of transcutaneous pacing (TCP) is advised. This recommendation is based on the 2019 Circulation guideline. [52][53]
• Bridge role: TCP is endorsed as a temporary bridge to transvenous pacing when bradycardia persists despite initial therapy, according to the same 2019 Circulation guideline. [52][53]

Bradycardia in Neurogenic Shock (Spinal Cord Injury)

• Atropine refractoriness: In the setting of spinal cord injury or neurogenic shock, bradycardia often does not respond to atropine because of unopposed parasympathetic activity; this observation is supported by the 2019 Circulation guideline. [52][53]

Transition to Transvenous Pacing

• Preparation for definitive pacing: When transcutaneous pacing is ineffective or prolonged pacing is required, clinicians should prepare for transvenous pacing. This guidance is drawn from the 2019 Circulation guideline. [52][53]

Guideline Recommendations for Management of Symptomatic Bradycardia

First‑Line Pharmacologic Therapy (Atropine)

• Atropine 0.5–1 mg IV push is the recommended initial treatment for any patient with symptomatic bradycardia (e.g., dizziness, syncope, chest discomfort, hypotension, or signs of inadequate perfusion). The dose may be repeated every 3–5 minutes, not exceeding a total of 3 mg (2–3 mg in post‑myocardial‑infarction patients). Class IIa, Level B recommendation from the ACC/AHA guidelines. [54] [55]

• Doses < 0.5 mg should be avoided because they can paradoxically worsen bradycardia via a parasympathomimetic effect. Class III (harm) recommendation. [54] [55]

• In patients with acute coronary syndrome or recent myocardial infarction, limit the total atropine dose to 2–3 mg and target a heart rate of ≈60 bpm to prevent tachycardia‑induced ischemia. Class IIa recommendation. 56

• Do not treat asymptomatic bradycardia (even if heart rate < 40 bpm) because vagal tone may be protective against ventricular fibrillation. Class III, Harm recommendation. [57] [56]

Situations in Which Atropine Is Expected to Be Effective

• Sinus bradycardia with hypotension, first‑degree AV block, Mobitz I (Wenckebach) AV block, sinus arrest or sino‑atrial pauses, and vagally mediated inferior‑MI bradycardia (typically within the first 6 hours). These rhythms arise at or above the AV node and respond well to atropine. Class IIa recommendation. [54] [55] 56

Situations in Which Atropine Is Ineffective or Contraindicated

• Infranodal (below the AV node) blocks – Mobitz II second‑degree AV block with wide QRS, third‑degree AV block with wide QRS, and anterior‑MI with new bundle‑branch block. Atropine does not improve conduction and may be harmful. Class III recommendation. [54] [55]

• Heart‑transplant recipients without autonomic re‑innervation – atropine may precipitate high‑grade AV block or sinus arrest. Class III recommendation.

Second‑Line Management When Atropine Fails

• If symptomatic bradycardia persists after the maximum atropine dose (3 mg total), initiate chronotropic infusions and/or transcutaneous pacing without delay. Class IIa recommendation. [54] [55]

Chronotropic Infusions

All infusion recommendations are *Class IIa*. [54] [55]

Transcutaneous Pacing

• Initiate immediately in hemodynamically unstable patients who do not respond to atropine. It serves as an urgent temporizing measure while preparing for transvenous or permanent pacing. Class IIa recommendation. [54] [55]

• Sedation/analgesia may be required because the procedure can be painful in conscious patients.

Transvenous Pacing

• Prepare for transvenous pacing if transcutaneous pacing is ineffective or prolonged pacing is anticipated. Historical complication rates range from 14 % to 40 % (likely lower with modern techniques). Class IIa recommendation. [54] [55] 57

Permanent Pacemaker Indications

• Permanent pacemaker implantation is indicated (Class I) when symptomatic bradycardia persists after all reversible causes have been excluded. [54] [55] 57

• Specific Class I indications include:

Pacing Mode Selection

• Atrial‑based pacing (AAI or DDD) is preferred over single‑chamber ventricular pacing in patients with symptomatic sinus node dysfunction and intact AV conduction. Class I recommendation. [54] [55] 57

• Dual‑chamber devices should be programmed to minimize ventricular pacing when AV conduction is preserved. Class I recommendation.

• Rate‑responsive programming is reasonable for patients with symptomatic chronotropic incompetence. Class IIa recommendation.

Critical Pitfalls to Avoid

• Do not exceed a total atropine dose of 3 mg (or 2–3 mg in post‑MI patients). Excess dosing can cause tachycardia and anticholinergic toxicity. Class III. [54] [55]

• Do not delay transcutaneous pacing in unstable patients while administering multiple atropine doses. Class III. [54] [55]

• Do not start dopamine before attempting atropine; atropine is safer and more appropriate as the first‑line agent. Class III. [54] [55]

• Do not treat asymptomatic bradycardia (even with HR < 40 bpm) because it may be protective. Class III, Harm. [57] [56]

• Do not use atropine for infranodal blocks (Mobitz II or third‑degree AV block with wide QRS); it will not improve conduction and may be harmful. Class III. [54] [55]

Dopamine Use for Symptomatic Sinus Bradycardia

Mechanism of Action

• Dopamine enhances sinus node automaticity through direct β₁‑adrenergic receptor stimulation and indirect release of norepinephrine, producing a chronotropic effect that is less pronounced than its inotropic effect on ventricular myocardium【58】.
• At therapeutic infusion rates of 5–20 µg·kg⁻¹·min⁻¹, the β₁‑mediated chronotropic effect predominates over other receptor actions【58】.

Guideline Recommendation (ACC/AHA)

• The ACC/AHA guidelines give dopamine a Class IIb recommendation (may be considered) for patients with sinus node dysfunction who have symptoms or hemodynamic compromise and a low likelihood of coronary ischemia【58】.

Dosing and Administration

• Initial infusion: 5–10 µg·kg⁻¹·min⁻¹ IV, titrated by 2–5 µg·kg⁻¹·min⁻¹ every 2 minutes based on heart‑rate and blood‑pressure response, with a maximum of 20 µg·kg⁻¹·min⁻¹【58】.
• Dopamine provides both chronotropic and inotropic support, making it useful when bradycardia is accompanied by hypotension or low cardiac output【58】.

Safety and Contra‑indications

• Dose‑dependent α‑adrenergic vasoconstriction: Infusions >10–20 µg·kg⁻¹·min⁻¹ shift the effect toward α‑adrenergic vasoconstriction, increasing afterload and the risk of arrhythmias without additional heart‑rate benefit【58】.
• Coronary ischemia risk: In the setting of acute coronary syndromes, dopamine‑induced heart‑rate acceleration may exacerbate myocardial ischemia or enlarge infarct size【58】.

Comparison with Alternative Chronotropic Agents

Isoproterenol

• Isoproterenol, a non‑selective β‑agonist, directly augments sinus node automaticity and atrioventricular nodal conduction without α‑mediated vasoconstriction, offering a more pure chronotropic effect【58】.
• Recommended dosing: 20–60 µg IV bolus or 1–20 µg·min⁻¹ infusion titrated to the desired heart‑rate response【58】.

Epinephrine

• Epinephrine is preferred when severe hypotension co‑exists with bradycardia because it delivers stronger combined chronotropic, inotropic, and vasopressor actions than dopamine【58】.
• Recommended dosing: 2–10 µg·min⁻¹ IV infusion (or 0.1–0.5 µg·kg⁻¹·min⁻¹)【58】.

Treatment Algorithm for Symptomatic Sinus Bradycardia

Dopamine Use for Symptomatic Bradycardia and Sinus Node Dysfunction

Dose‑Dependent Hemodynamic and Chronotropic Effects

• Low‑dose dopamine (≤ 2 µg·kg⁻¹·min⁻¹) primarily activates dopaminergic (DA₁/DA₂) receptors, producing vasodilation in renal, mesenteric, and cerebral vascular beds with minimal direct increase in sinoatrial (SA) node firing rate. – American College of Cardiology/American Heart Association (ACC/AHA) 59
• Moderate‑dose dopamine (5–20 µg·kg⁻¹·min⁻¹) provides robust β₁‑adrenergic stimulation of SA nodal pacemaker cells, raising intracellular cAMP and PKA activity, which accelerates phase‑4 diastolic depolarization and markedly increases heart rate. – ACC/AHA 59
• High‑dose dopamine (> 20 µg·kg⁻¹·min⁻¹) shifts the pharmacologic profile toward α‑adrenergic activation, causing profound peripheral vasoconstriction, increased afterload, and higher myocardial oxygen demand without proportional heart‑rate benefit; pro‑arrhythmic effects become prominent. – ACC/AHA 59

Guideline Recommendations for Dopamine Administration

• The ACC/AHA guidelines recommend initiating dopamine at 5–10 µg·kg⁻¹·min⁻¹ for symptomatic bradycardia, titrating by 2–5 µg·kg⁻¹·min⁻¹ every 2 minutes to achieve a target heart rate of ≈ 60 bpm. – ACC/AHA, Class IIb (may be considered) 60
• When used in the therapeutic range (5–20 µg·kg⁻¹·min⁻¹), dopamine provides both chronotropic and inotropic support, making it useful when bradycardia is accompanied by hypotension or low cardiac output. – ACC/AHA 59
• The ACC/AHA assign dopamine a Class IIb recommendation for symptomatic sinus node dysfunction with hemodynamic compromise in patients at low likelihood of coronary ischemia. – ACC/AHA 60
• Standard dosing protocol: start at 5 µg·kg⁻¹·min⁻¹, increase by 5 µg·kg⁻¹·min⁻¹ every 2 minutes based on heart‑rate and blood‑pressure response, with a maximum dose of 20 µg·kg⁻¹·min⁻¹. – ACC/AHA 60

Safety, Contraindications, and Clinical Warnings

• Doses > 20 µg·kg⁻¹·min⁻¹ are explicitly warned against by the ACC/AHA because they are associated with excessive vasoconstriction, tachyarrhythmias, and heightened risk of myocardial ischemia, especially in patients with coronary artery disease. – ACC/AHA [59][60]
• In acute coronary syndromes, dopamine should be used with extreme caution; the drug‑induced increase in heart rate raises myocardial oxygen consumption and may exacerbate ischemia or enlarge infarct size. – ACC/AHA 59
• In patients with infranodal atrioventricular (AV) block (type II second‑degree or third‑degree with wide QRS), dopamine does not improve conduction and may be harmful; transcutaneous pacing is the preferred intervention. – ACC/AHA 60
• Atropine (0.5–1 mg IV, repeatable up to 3 mg) remains the first‑line agent for symptomatic bradycardia; dopamine is reserved for cases refractory to atropine. – ACC/AHA 60

Dopamine as a Second‑Line Chronotropic Agent for Symptomatic Bradycardia

Indications and Guideline Recommendations

• The ACC/AHA gives dopamine a Class IIb recommendation for patients with sinus node dysfunction who remain symptomatic or hemodynamically compromised after atropine, especially when hypotension coexists and coronary ischemia is unlikely. 61

First‑Line Therapy Overview

• Atropine (0.5–1 mg IV push) is the first‑line agent for any patient with symptomatic bradycardia (e.g., altered mental status, chest pain, dyspnea, systolic BP < 90 mmHg, or shock) and should be repeated every 3–5 minutes up to a total of 3 mg; doses < 0.5 mg may worsen bradycardia. 61

Dopamine Dosing and Titration

• Initial infusion: start at 5 µg/kg/min IV (some sources allow 5–10 µg/kg/min) for patients requiring chronotropic support. 61
• Titration: increase by 5 µg/kg/min every 2 minutes based on heart‑rate and blood‑pressure response, aiming for the therapeutic window. 61
• Therapeutic range: 5–20 µg/kg/min provides optimal β₁‑adrenergic chronotropic and inotropic effects without excessive α‑adrenergic vasoconstriction. 61
• Maximum dose: do not exceed 20 µg/kg/min; higher doses shift activity toward α‑adrenergic vasoconstriction, increase afterload, and raise the risk of arrhythmias without further heart‑rate benefit. 61

Mechanism of Action at Therapeutic Doses

• At 5–20 µg/kg/min, dopamine enhances sinus‑node automaticity by accelerating phase‑4 diastolic depolarization through β₁‑adrenergic receptor stimulation and indirect norepinephrine release, delivering both chronotropic and inotropic support useful when bradycardia is accompanied by hypotension or low cardiac output. 61

Comparison with Alternative Agents

• Epinephrine (2–10 µg/min IV) is preferred over dopamine when severe hypotension demands strong combined chronotropic and vasopressor effects, or in heart‑transplant recipients where atropine is contraindicated. 61
• Isoproterenol (20–60 µg IV bolus or 1–20 µg/min infusion) may be favored in ischemic cardiomyopathy because it provides pure β‑adrenergic chronotropic and inotropic effects without α‑mediated vasoconstriction. 61

Contraindications and Safety Warnings

• Infranodal AV block (Mobitz II or third‑degree with wide QRS) is a contraindication; dopamine does not improve conduction below the AV node and may be harmful—transcutaneous pacing is indicated instead. 61
• Acute coronary syndrome or recent myocardial infarction: dopamine‑induced tachycardia can increase myocardial oxygen demand and exacerbate ischemia; use only with extreme caution and limit heart‑rate rise to ≈60 bpm. 61
• Dose‑related adverse effects: doses > 20 µg/kg/min cause pronounced α‑adrenergic vasoconstriction, leading to peripheral vasoconstriction, increased afterload, and pro‑arrhythmic events (ventricular tachycardia/fibrillation). Continuous monitoring for chest pain, ST changes, and arrhythmias is required. 61

Pacing Recommendations

• Transcutaneous pacing should not be delayed in hemodynamically unstable patients while awaiting response to atropine or dopamine; it carries a Class IIa recommendation as a bridge to transvenous or permanent pacing. 61
• Permanent pacemaker implantation receives a Class I recommendation when symptomatic bradycardia persists after correction of reversible causes (medications, electrolytes, thyroid dysfunction). 61

Special Clinical Scenarios

• Neurogenic shock (spinal cord injury): bradycardia is often refractory to atropine; dopamine 5–20 µg/kg/min (or aminophylline 6 mg/kg IV over 20–30 min) is an appropriate alternative. 61
• Post‑heart‑transplant patients: dopamine is not preferred; aminophylline or theophylline is recommended because atropine is contraindicated and may precipitate high‑degree AV block. 61

Atropine Use During Continuous Norepinephrine Infusion

Pharmacologic Compatibility

• Continuing a norepinephrine infusion at its current rate while administering intravenous atropine does not result in pharmacologic interference; the two agents act via distinct mechanisms and can be given together safely. Evidence level: observational data from the European Journal of Heart Failure (2008). 62

Clinical Recommendations in Resuscitation

• Resuscitation protocols advise not to withhold atropine in patients already receiving norepinephrine, because the drugs are complementary and are frequently used together when managing symptomatic bradycardia in hemodynamically unstable patients. Evidence level: observational data from the European Journal of Heart Failure (2008). 63

Management of Symptomatic Bradyarrhythmia

Initial Assessment and Stabilization

• Symptomatic bradycardia is defined as a heart rate < 50 bpm accompanied by signs of poor perfusion (e.g., altered mental status, ischemic chest discomfort, acute heart failure, systolic BP < 80–90 mmHg, syncope, or shock)【64】.
• Immediate stabilization includes securing the airway and providing assisted ventilation as needed【65】.
• Continuous cardiac monitoring, blood‑pressure measurement, and pulse‑oximetry should be instituted promptly to identify the rhythm and guide therapy【65】.
• A 12‑lead ECG should be obtained without delaying treatment【65】.

First‑Line Pharmacologic Therapy: Atropine

• Administer atropine 0.5–1 mg IV push immediately; repeat every 3–5 min as needed, with a maximum cumulative dose of 3 mg (2–3 mg in post‑MI patients) while preparing transcutaneous pacing if instability persists【64】【66】.
• Doses < 0.5 mg may paradoxically worsen bradycardia via a parasympathomimetic effect and should be avoided【64】【66】.

Situations in Which Atropine Is Likely Effective (Nodal‑Level Blocks)

• Sinus bradycardia and first‑degree AV block respond to atropine【64】【66】.
• Mobitz I (Wenckebach) second‑degree AV block improves with atropine【64】【66】.

Situations in Which Atropine Is Ineffective or Contraindicated (Infranodal Blocks, Class III)

• Mobitz II second‑degree AV block with a wide QRS complex does not improve with atropine and may be harmed【64】【66】.
• Third‑degree AV block with a wide QRS complex is similarly unresponsive to atropine【64】【66】.
• Anterior myocardial infarction with new bundle‑branch block is a contraindication to atropine use【64】【66】.

Special Populations

• In heart‑transplant recipients lacking autonomic re‑innervation, atropine can precipitate high‑degree AV block; epinephrine is preferred【64】.
• In acute coronary ischemia or myocardial infarction, atropine should be used cautiously, limiting total dose to 2–3 mg and targeting a heart rate of ≈ 60 bpm【64】.

Second‑Line Therapies When Atropine Fails

Transcutaneous Pacing (TCP)

• TCP should be initiated immediately in unstable patients who do not respond to atropine; pacing must not be delayed while additional atropine doses are administered【64】【66】.
• Class IIa recommendation for unstable bradycardia refractory to atropine【64】【66】.
• TCP serves as an urgent bridge to transvenous or permanent pacing【64】【66】.

Chronotropic Infusions

Reversible Causes and Definitive Management

• Prior to permanent pacing, reversible etiologies must be identified and treated: drug toxicity (β‑blockers, calcium‑channel blockers, digoxin, amiodarone), Lyme carditis, hypothyroidism, and cardiac sarcoidosis (the latter may warrant permanent pacing with defibrillator capability)【64】【66】.
• In patients on chronic, necessary antiarrhythmic or β‑blocker therapy who develop symptomatic second‑ or third‑degree AV block, proceeding directly to permanent pacing without drug washout is reasonable【64】【66】.

Permanent Pacemaker Indications (Class I)

• Permanent pacemaker implantation is indicated when symptomatic bradycardia persists after exclusion of reversible causes, including:
  
  • Documented sinus node dysfunction with symptomatic bradycardia【64】.
  • High‑grade AV block (Mobitz II or third‑degree) associated with symptoms【64】.

Critical Pitfalls to Avoid

• Do not treat asymptomatic bradycardia (even HR < 40 bpm) as it may be protective against ventricular fibrillation (Class III)【64】.
• Do not delay transcutaneous pacing in unstable patients while administering multiple atropine doses【64】.
• Do not exceed a total atropine dose of 3 mg (or 2–3 mg in post‑MI patients) to avoid tachycardia and anticholinergic toxicity【64】.
• Do not use atropine for infranodal blocks (Mobitz II or third‑degree with wide QRS) as it will not improve conduction and may worsen the block【64】.
• Do not exceed dopamine 20 µg/kg/min to prevent excessive vasoconstriction and arrhythmias【64】.

All recommendations are based on guidelines from the American Heart Association (AHA) as reflected in the cited literature.

Management of Symptomatic Bradyarrhythmia

Definition & Initial Assessment

• Symptomatic bradycardia is defined as a heart rate < 50 bpm accompanied by altered mental status, ischemic chest discomfort, acute heart failure (dyspnea or pulmonary edema), or syncope/near‑syncope; these clinical features identify patients who require urgent therapy【67】.

First‑Line Pharmacologic Therapy – Atropine

• The American Heart Association recommends immediate IV atropine 0.5–1 mg push for hemodynamically compromised symptomatic bradycardia, repeating every 3–5 min as needed, with a maximum total dose of 3 mg (or 2–3 mg in post‑myocardial‑infarction patients) while preparing transcutaneous pacing pads【67】 (Class I).
• Doses < 0.5 mg should be avoided because they may paradoxically worsen bradycardia via a parasympathomimetic effect【67】 (Class I).
• Atropine is effective (Class I) for:
  
  • Sinus bradycardia,
  • First‑degree AV block,
  • Mobitz I (Wenckebach) second‑degree AV block, and
  • Vagal‑mediated bradycardia (e.g., inferior MI, airway manipulation)【67】.
• Atropine is ineffective/contraindicated (Class III) for:
  
  • Mobitz II second‑degree AV block with wide QRS,
  • Third‑degree AV block with wide QRS,
  • Anterior MI with new bundle‑branch block, and
  • Heart‑transplant patients without autonomic re‑innervation (risk of paradoxical high‑grade AV block)【67】.

Second‑Line Therapy – Electrical & Pharmacologic

Transcutaneous Pacing (TCP)

• In unstable patients who do not respond to atropine, the American Heart Association advises immediate initiation of TCP without delaying for additional atropine doses (Class IIa)【67】.
• TCP serves as a bridge to transvenous or permanent pacing【67】 (Class IIa).

Chronotropic Infusions (Class IIb)

• Dopamine doses > 20 µg/kg/min cause excessive vasoconstriction and arrhythmias without additional heart‑rate benefit【67】 (Class IIb).
• All chronotropic agents increase myocardial oxygen demand and may exacerbate ischemia in acute coronary syndromes; heart‑rate elevation should be limited to ≈60 bpm【67】 (Class IIb).

Identification & Treatment of Reversible Causes

• Before permanent pacing, the American Heart Association mandates identification and correction of reversible etiologies (Class I)【67】【68】.
• Reversible factors include:
  
  • Drug toxicity – taper or discontinue β‑blockers, non‑dihydropyridine calcium‑channel blockers, digoxin, amiodarone, quetiapine【67】.
  • Metabolic disturbances – correct hyperkalemia and hypothyroidism【67】【68】.
  • Infectious – treat Lyme carditis medically; temporary pacing may be needed【67】【68】.
  • Inflammatory – cardiac sarcoidosis may require permanent pacing with defibrillator capability without waiting for reversibility (Class IIa)【67】【68】.
• Exception: patients on chronic, medically necessary antiarrhythmic or β‑blocker therapy who develop symptomatic second‑ or third‑degree AV block may proceed directly to permanent pacing without drug washout (Class IIa)【67】【68】.

Indications for Permanent Pacemaker

• Permanent pacing is indicated (Class I) when symptomatic bradycardia persists after reversible causes are excluded【67】【68】. Specific indications:
  
  • Documented sinus‑node dysfunction with symptoms【67】【68】.
  • Symptomatic sinus bradycardia caused by guideline‑directed medical therapy when no alternative exists【68】.
  • High‑grade AV block (Mobitz II or third‑degree) with symptoms【67】【68】.

Pacing Mode Selection

• For symptomatic sinus‑node dysfunction with intact AV conduction, atrial‑based pacing (AAI or DDD) is preferred over single‑chamber ventricular pacing (Class I)【67】【68】.
• Dual‑chamber devices should be programmed to minimize ventricular pacing when AV conduction is preserved (Class I)【67】【68】.
• Rate‑responsive programming is reasonable for patients with chronotropic incompetence (Class IIa)【68】.

Critical Pitfalls to Avoid

• Do not treat asymptomatic bradycardia (even HR < 40 bpm) – such patients may benefit from protective vagal tone (Class III) – citation omitted (ignore).
• Do not delay transcutaneous pacing in unstable patients while administering additional atropine doses【67】 (Class IIa).
• Do not exceed a total atropine dose of 3 mg (or 2–3 mg post‑MI) to avoid tachycardia and anticholinergic toxicity【67】 (Class I).
• Do not use atropine for infranodal blocks (Mobitz II or third‑degree with wide QRS) as it will not improve conduction and may worsen block【67】 (Class III).
• Do not exceed dopamine 20 µg/kg/min; higher doses cause vasoconstriction and arrhythmias without benefit【67】 (Class IIb).

Management of Unstable Bradyarrhythmias – ACC/AHA/HRS Guideline Recommendations

Agents Not Recommended

• The 2018 ACC/AHA/HRS bradycardia guideline does not recommend the use of dobutamine or noradrenaline (norepinephrine) for the treatment of unstable bradyarrhythmias, as they are absent from the guideline’s first‑ and second‑line options. 69

First‑Line Therapy: Atropine

• Atropine 0.5–1 mg IV push should be administered immediately to any patient with symptomatic bradycardia (e.g., altered mental status, chest pain, acute heart failure, systolic BP < 80–90 mmHg, or shock). 69
• The dose may be repeated every 3–5 minutes up to a maximum total of 3 mg (or 2–3 mg in post‑myocardial‑infarction patients). 69
• Doses < 0.5 mg are discouraged because they can paradoxically worsen bradycardia via parasympathomimetic effects. 69
• Indication limitation: Atropine is effective only for nodal‑level blocks (sinus bradycardia, first‑degree AV block, Mobitz I). It is a Class III (contraindicated) therapy for infranodal blocks (Mobitz II, third‑degree AV block with wide QRS), where it may aggravate the conduction disturbance. 69

Second‑Line Chronotropic Infusions (When Atropine Fails or Is Contraindicated)

Dopamine (Preferred for Most Cases)

• Initiate an IV infusion at 5–10 µg·kg⁻¹·min⁻¹. 69
• Titrate by 5 µg·kg⁻¹·min⁻¹ every 2 minutes based on heart‑rate and blood‑pressure response. 69
• The therapeutic range is 5–20 µg·kg⁻¹·min⁻¹, providing optimal β₁‑adrenergic chronotropic and inotropic effects. 69
• Do not exceed 20 µg·kg⁻¹·min⁻¹; higher doses produce excessive α‑adrenergic vasoconstriction and arrhythmias without additional heart‑rate benefit. 69

Epinephrine (Preferred When Severe Hypotension Is Present)

• Start an IV infusion at 2–10 µg·min⁻¹ (approximately 0.1–0.5 µg·kg⁻¹·min⁻¹). 69
• Epinephrine is preferred over dopamine in patients with severe hypotension because it delivers combined chronotropic, inotropic, and vasopressor effects. 69
• It is also the preferred agent in heart‑transplant recipients where atropine is contraindicated. 69

Third‑Line Therapy: Transcutaneous Pacing

• Immediate transcutaneous pacing is indicated for unstable patients who do not respond to atropine; pacing should not be delayed while administering additional atropine doses. 69
• This intervention carries a Class IIa recommendation for unstable bradycardia refractory to atropine. 69

Safety Considerations

• All chronotropic agents increase myocardial oxygen demand and may exacerbate ischemia in acute coronary syndromes; the target heart rate is ≈ 60 bpm, avoiding aggressive rate elevation. 69
• Dopamine > 20 µg·kg⁻¹·min⁻¹ and noradrenaline (when used off‑label) are associated with vasoconstriction and arrhythmias without additional benefit, reinforcing the need to stay within recommended dosing limits. 69
• Atropine must not be used for infranodal blocks (Mobitz II, third‑degree AV block with wide QRS) because it does not improve conduction and may be harmful. 69